Novo Nordisk’s Wegovy and copyright, both equally run by semaglutide, have revolutionized being overweight procedure through unparalleled weight loss results.In October 2024, Novo Nordisk published a analyze on scientific journal Character a few novel glucose-delicate insulin NNC2215 that will lessen the chance of hypoglycemia in animal products.